AR056720A1 - SUBSTTED TIAZOL COMPOSITE PHARMACEUTICALLY COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A MEDICINAL PRODUCT - Google Patents

SUBSTTED TIAZOL COMPOSITE PHARMACEUTICALLY COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A MEDICINAL PRODUCT

Info

Publication number
AR056720A1
AR056720A1 ARP060104641A ARP060104641A AR056720A1 AR 056720 A1 AR056720 A1 AR 056720A1 AR P060104641 A ARP060104641 A AR P060104641A AR P060104641 A ARP060104641 A AR P060104641A AR 056720 A1 AR056720 A1 AR 056720A1
Authority
AR
Argentina
Prior art keywords
prepare
substted
tiazol
composite
medicinal product
Prior art date
Application number
ARP060104641A
Other languages
Spanish (es)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR056720A1 publication Critical patent/AR056720A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un compuesto de tiazol substituido de formula (1) en la que: R1 es etilo, propilo o isopropilo y R2 es hidrogeno, cloro, fluor o metilo; o una sal farmacéuticamente aceptable de los mismos. Los compuestos son agentes de apertura de canales de K activados por calcio de alta conductancia (canales Bkca), de interés en el campo de las afecciones urinarias. Composicion farmacéutica que lo comprende y su uso para preparar un medicamento util para tratar la vejiga hiperactiva (OAB).A substituted thiazole compound of formula (1) in which: R1 is ethyl, propyl or isopropyl and R2 is hydrogen, chlorine, fluorine or methyl; or a pharmaceutically acceptable salt thereof. The compounds are K channel opening agents activated by high conductance calcium (Bkca channels), of interest in the field of urinary disorders. Pharmaceutical composition that comprises it and its use to prepare a useful medication to treat overactive bladder (OAB).

ARP060104641A 2005-10-26 2006-10-24 SUBSTTED TIAZOL COMPOSITE PHARMACEUTICALLY COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A MEDICINAL PRODUCT AR056720A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73029805P 2005-10-26 2005-10-26

Publications (1)

Publication Number Publication Date
AR056720A1 true AR056720A1 (en) 2007-10-17

Family

ID=37968661

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104641A AR056720A1 (en) 2005-10-26 2006-10-24 SUBSTTED TIAZOL COMPOSITE PHARMACEUTICALLY COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A MEDICINAL PRODUCT

Country Status (4)

Country Link
AR (1) AR056720A1 (en)
PE (1) PE20070530A1 (en)
TW (1) TW200732314A (en)
WO (1) WO2007051133A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009125870A1 (en) 2008-04-09 2009-10-15 Mitsubishi Tanabe Pharma Corporation Pyrimidine, pyridine and triazine derivatives as maxi-k channel openers.
KR102676631B1 (en) * 2020-10-07 2024-06-19 광주과학기술원 Composition for preventing or treatment of overactive bladder

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4746741A (en) * 1986-06-19 1988-05-24 Eastman Kodak Company N,N'-bis[2-(3-methylphenyl)ethyl]-perylene-3,4:9,10-bis (dicarboximide) compound use thereof in multi-active photoconductive insulating elements exhibiting far red sensitivity
IE73235B1 (en) * 1991-03-25 1997-05-21 Akzo Nv 4-aryl-thiazole or imidazole derivatives
HU208429B (en) * 1991-05-03 1993-10-28 Gyogyszerkutato Intezet Process for producing 1-/3-chloro-phenyl/-4-methyl-7,8-dimethoxy-5h-2,3-benzodiazepine of high purity
US5668286A (en) * 1994-03-15 1997-09-16 Pharmacia & Upjohn Company Oxazolidinone derivatives and pharmaceutical compositions containing them
JP4073786B2 (en) * 2001-04-16 2008-04-09 田辺三菱製薬株式会社 High conductance calcium-sensitive K channel opener
GB0121033D0 (en) * 2001-08-30 2001-10-24 Novartis Ag Organic compounds
US7057040B2 (en) * 2002-02-07 2006-06-06 Council Of Scientific And Industrial Research Substituted aryl alkenoic acid heterocyclic amides

Also Published As

Publication number Publication date
WO2007051133A2 (en) 2007-05-03
TW200732314A (en) 2007-09-01
PE20070530A1 (en) 2007-05-31
WO2007051133A3 (en) 2007-12-13

Similar Documents

Publication Publication Date Title
GT200600163A (en) NEW THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION
EA200401194A1 (en) Glucosocorticoid Mimetics, Methods for Their Production, Pharmaceutical Compositions and Their Use
AR051405A1 (en) 2-CARBOXAMIDE (3-AMINO) THIOPHENE COMPOUNDS
PE20091556A1 (en) FUSED HETEROCYCLIC DERIVATIVE AND ITS USE
PA8591701A1 (en) PIRROLOPIRIMIDINE DERIVATIVES
ES2422557T3 (en) Compounds and compositions as modulators of the Hedgehog route
CL2007001918A1 (en) SUBSTITUTED HETEROARILY DERIVATIVE COMPOUNDS; METHOD FOR THE PREPARATION OF COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF PAIN, DEPRESSION, ALZHEIMER'S DISEASE AND HYPERTENSION BETWEEN OTHERS.
BRPI0518993A2 (en) compound or a pharmaceutically acceptable salt, solvate or ester thereof, pharmaceutical composition, and use of a compound
HN2004000319A (en) "{1,8} NAFTIRIDIN-2-ONAS AND RELATED COMPOUNDS FOR THE TREATMENT OF CHICHOPHRENIA"
EA200702498A1 (en) N- (PYRIDIN-2-IL) SULPHONAMIDE DERIVATIVES
BRPI0417717A (en) compound, pharmaceutical composition, and use of a compound
CL2011000835A1 (en) Compounds derived from spiro-oxindole; sodium channel modulators; pharmaceutical composition comprising said compound; and use in the treatment of pain, depression, cardiovascular, respiratory, psychiatric diseases, among others.
ECSP088499A (en) NEW COMPOUNDS OF 2-AMINO-IMIDAZOL-4-ONA AND ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR USE IN THE TREATMENT OF COGNITIVE ALTERATION, ALZHEIMER'S DISEASE, NEURODEGENERATION AND DEMENTIA
CL2008002295A1 (en) Alkylsulfonyl-substituted thiazolid derivative compounds; pharmaceutical composition; and use for the treatment of hepatitis c.
EA200971081A1 (en) PURINUM DERIVATIVES AND THEIR APPLICATION AS A TALL-SIMILAR RECEPTOR MODULATORS 7
UY27740A1 (en) NEW COMPOUNDS
CL2008001868A1 (en) COMPOUNDS DERIVED FROM N- (2- (HETARIL) ARIL) ARILSULPHONAMIDS AND N- (2- (HETARIL) HETARIL) ARILSULFONAMIDS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE INTESTINE, ALLERGIC DISEASE
HK1079446A1 (en) Pharmeceutical solid dispersions of modafinil compounds
GT200500309A (en) DERIVATIVES OF SULFONILBENCILIMIDAZOL
ATE556074T1 (en) NEW IMIDAZOÄ1,5-AÜPYRIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
BRPI0611705A2 (en) compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, and use of compound
GT200600161A (en) NEW THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS
DK1697371T3 (en) Azabicyclic heterocyclic compounds as cannabinoid receptor modulators
UY30414A1 (en) METHANE SULFONATES, PROPANE-1-SULPHONATES AND CYCLOPROPAN SULPHONATES REPLACED WITH [2,3,4,8-TETRAHYDROIMIDAZO- [1,5-AL-PYRIMIDIN-8-IL] -PHENYLL, PHARMACEUTICAL COMPOSITIONS AND APPLICATIONS.
UY29234A1 (en) ADAMANTAN DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, BOTH PREPARATION PROCEDURES AND APPLICATIONS.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal